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IB kinases increase Myc protein stability and
enhance progression of breast cancer cells
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Abstract
Background: Both IB kinase (IKK) complex and oncgenic protein Myc play important roles in cancer progression,
including cancer cell invasiveness and metastasis. The levels of Myc is regulated by the phosphorylation of Myc at
Thr58 and Ser62.
Results: In this study, we show that the expression of Myc is associated with IKKa and IKKb in breast cancers and
that Myc is an IKKs substrate. Suppression of IKK activity by either chemical inhibitor or transfection of kinase-dead
mutants decreases the phosphorylation of Myc at Ser62 and enhances the degradation of Myc. Consequently,
these treatments decrease the tumorigenic and invasive ability of breast cancer cells. Furthermore, doxorubicin, a
frequently used anticancer drug in breast cancer, activates IKKs and Myc, thereby increasing invasiveness and
tumorigenesis of breast carcinoma MCF7 cells. Inhibition of IKKs prevents these doxorubicin-induced effects.
Conclusions: Our study indicates that IKKs tightly regulate Myc expression through prolonging protein stability,
and suggests that IKKs are potentially therapeutic targets and that suppression of IKKs may be used following
chemotherapy to reduce the risk of treatment-induced tumor progression.
Background
The IKK complex is composed of two kinase catalytic
subunits IKKa and IKKb and a non-kinase scaffold pro-
tein IKKg [1-3]. The complex functions as an upstream
kinase involved in the activation of nuclear factor kappa
B(NF-B)by phosphorylation of the NF-B inhibitory
molecule, IBa, resulting in the subsequent degradation
of IBa through the ubiqutin/proteasome pathway. The
released NF-B translocates into the nucleus and then
regulates the expression of multiple genes [1,4,5].
Numerous reports have indicated that the functions of
IKKs are necessary for cancer cell survival and progres-
sion [3,6-8].
Most studies regarding IKKs are actually focused on
their downstream molecule, NF-B, and the thinking
that IKKs might be therapeutic targets is trying to indir-
ectly suppress NF-B activation [1,9]. However, accumu-
lating evidence has indicated that IKKs have NF-B-
independent effects on multiple proteins [1,10]. For
example, IKKb phosphorylates tumor suppressor
FOXO3a, and consequently induces FOXO3a nuclear
exclusion and degradation, thereby promoting tumor
survival [11]. Interesting, IKKa and IKKb may have
opposite effect on certain proteins. For example, IKKa
increases but IKKb decreases the transcriptional activity
and protein level of b-catenin [12,13]. The biological
significance of IKKs is getting complicated and requires
further characterization. The identification of new sub-
strates of IKKs is important for the understanding of
IKKs functions in cancer biology.
The oncogenic Myc protein is a transcription factor
that regulates a wide spectrum of downstream genes
involved in cancer cell metabolism, growth, and progres-
sion [14-17], and it is well documented that Myc plays
an important role in breast cancer metastasis [17-19].
Abnormal expression of Myc is frequently associated
with cancer progression [20-23]. Several transcription
factors, including NF-B, E2F, STAT, and b-catenin, are
involved in the regulation of Myc expression [24,25].
Inhibition of these transcription factors suppresses can-
cer cell survival in part by decreasing Myc expression.
The Myc protein level is further regulated by control
of protein stability, which is determined by a compli-
cated protein kinase/phosphatase system.
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Phosphorylation of Myc at Ser62 increases protein stabi-
lity. The kinases ERK (extracellular signal-regulated
kinase), JNK (c-Jun N-terminal kinase) and cdk1 (cyclin-
dependent kinase 1) have been identified to phosphory-
late Myc at Ser62 [16,26,27]. The Ser62 phosphorylated
Myc is further phosphorylated at Thr58 by glycogen
synthase kinase 3b. The Thr58/Ser62 dual phosphory-
lated Myc is acted on by protein phosphatase 2A
[PP2A] to dephosphorylate Ser62. Then, monopho-
sphorylated Myc (at Thr58) is degraded by ubiquitin/
proteosome system. A cellular PP2A inhibitor cip2A
which is overexpressed in several cancers has been
shown to increase Myc levels via suppression of PP2A
activity [16,28,29]. Given the fact that numerous intra-
and extra-cellular stimuli regulate the activation of Myc,
it is expected that other unidentified kinases may be
also involved.
In this study, we investigated the association of Myc
and IKK/NF-B in breast cancer. Interestingly, IHC
staining of breast cancer specimens showed that the
expression of Myc was closely associated with that of
IKKs but not with NF-B p65. We demonstrated that
IKKa and IKKb increased Myc protein levels by
prolonging protein stability, and this consequently pro-
moted the tumorigenic and invasive activity of breast
cancer cells. Our results also indicated that IKKa but
not IKKb directly interacted with Myc. In addition, we
showed that a conventional anti-cancer drug, doxorubi-
cin, activated the IKKs-Myc pathway which might
enhance tumor progression. Together, our study indi-
cated that suppression of IKKa and IKKb may decrease
basal and stress-induced Myc protein levels. The latter




The specimens were acquired between 2009 and 2010
from patients with infiltrating ductal carcinoma of the
breast, prior to chemotherapy without adjuvant, and
were kindly provided by the Department of Pathology,
National Taiwan University Hospital, on the basis of
their availability. Use of these tissue materials followed
the regulations of the research ethics committee of the
National Taiwan University Hospital.
Immunohistochemical study (IHC)
The tumor tissue embedded in paraffin was cut in 5-μM
section, and then de-paraffinized in xylene and rehy-
drated. For antigen-retrieval, the sections were incubated
with 10 mM sodium citrate buffer (pH 6.0) in a boiling
water bath for 15 minutes. The slides were then incu-
bated with 3% H2O2 in methanol to block endogenous
peroxidase activity. IHC staining was performed using a
streptavidin-biotin-peroxidase kit(Vectastain Universal
Quick Kit; Vector Laboratories, Burlingame, CA, USA)
according to the manufacturer’s instructions. DAB/chro-
mogen system (Dako Northern America, Inc.)was used
to develop the image. The antibodies, including anti-
IKKa (sc-7183), anti-IKKb (sc-7329), anti-NF-B p65
(sc-372) and anti-Myc (sc-40), were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
were used at a 1:50 dilution. The staining was judged
and counted by a researcher who was blinded regarding
the corresponding patient.
Cells and reagents
Breast cancer cell line MCF7 was purchased from the
American Type Culture Collection. The cells were cul-
tured in Dulbecco’s Modified Eagle Medium supplemen-
ted with 10% FCS and incubated in 37°C with 5% CO2.
All chemicals and reagents used were purchased from
Calbiochem or Sigma-Aldrich.
Plasmid and transfection
The IKKa and IKKb (both wild-type and kinase-dead
mutant) expression vectors were kindly provided by Pro-
fessor WC Greene (Gladstone Institute of Virology and
Immunology, University of California, San Francisco),
and were used to transfect MCF7 cells using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA). The trans-
fected cells were selected and maintained with complete
medium containing 500 μg/ml G418.
Coimmunoprecipitation and Western blot analysis
Whole cell lysates were prepared in RIPA solution con-
taining a cocktail of protease and phosphatase inhibitors,
or the cells were fractionated into cytoplasmic and
nuclear fractions. For cellular fractionation, the cells were
harvested and resuspended in hypotonic solution (Buffer
1; 1 mM KCl, 0.2 mM MgCl2, 4 mM Tris, pH7.6, con-
taining a cocktail of protease inhibitors) for 20 minutes
on ice. The cells were then lysed by adding lysis buffer
(Buffer 1 containing 1% Triton X-100) and vigorously
vortexed for 20 seconds, and then centrifuged at 1500
rpm for 5 minutes. The supernatant was collected as
cytoplasmic fraction, and the pellet was washed once
with PBS buffer and then lysed by RIPA buffer as nuclear
fraction. After determination of protein concentration of
each lysates, the aliquots (15 μg) were subjected to Wes-
tern blot analysis. For coimmunoprecipitation, target
proteins were immunoprecipitated from whole cell
lysates (500 μg) by adding 2 μg antibody at 4°C overnight
followed by protein A/G agarose adsorption(Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The complex was
washed once with RIPA buffer containing 500 mM NaCl,
once with RIPA buffer containing 250 mM NaCl, and
two times with RIPA buffer. The washed complex was
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then resolved in SDS-sample buffer and was subjected to
Western blot analysis. The antibodies used were as fol-
lows: anti-NF-B p65, anti- NF-B p50, anti-pMyc, anti-
Max, and anti-twist antibodies from Santa Cruz Biotech-
nology; anti-IKKa, anti-IKKb, anti-Myc, and anti-cyclin
D1 antibodies from Cell Signaling; anti-pS62 Myc anti-
body from Abnova (Taipei City, Taiwan); and anti-pT58
Myc antibody from Abgent(San Diego, CA, USA).
Confocal microscopy observation
Breast cancer tissue slides previously identified as posi-
tive or negative staining by IHC analysis were used for
confocal microscopy observation. The process for de-
paraffin and antigen retrieval was as in the IHC staining
protocol. The slides were dual-stained using rabbit anti-
IKKa and mouse anti-Myc antibodies coupled with
FITC-conjugated goat anti-rabbit IgG and rodamine-
conjugated donkey anti-mouse IgG antibodies, or goat
anti-IKKb and mouse anti-Myc antibodies coupled with
FITC-conjugated donkey anti-goat IgG and rodamine-
conjugated donkey anti-mouse IgG antibodies. The
images were captured using a confocal microscope (TCS
SP2; Leica, Wetzlar, Germany) at the confocal micro-
scopy core-facilities of the National Taiwan University
Hospital.
Quantitative RT-PCR
RNA was extracted using Trizol reagent (Invitrogen).
cDNAs were synthesized by a reverse transcription reac-
tion. The expression of gene was quantified using SYBR
Green PCR Master Mix on an ABI PRISM 7900 system
(Applied Biosystems). The primers used were 5’-
TCGACTACGACTCGGTGCAG (forward), 5’-TGG
GCAGCAGCTCGAATTTC (reverse) for Myc; and 5’-
TCGGAGTCAACGGATTTGG(forward), 5’-GAAT
TTGCCATGGGTGGAAT (reverse) for GAPDH. The
expression level of GAPDH was used a control. The
PCR reaction was performed with the following pro-
gram: 95°C for 10 minutes, and then 40 cycles of 95°C
for 15 seconds and 60°C for 1 minute. The relative
expression level of the target gene was calculated using
the ΔCt (threshold cycle) method: relative expression =
2-ΔCt, where ΔCt = Ct (target gene) - Ct (control gene).
Determination of RNA and protein stability
To determine the stability of mRNA, the cells were trea-
ted with 5 μg/ml actinomycin D to block new mRNA
synthesis. Total RNAs were extracted at different time
point after treatment. Random-primed reverse tran-
scribed cDNA was subjected to qPCR analysis to deter-
mine the relative expression levels of the Myc and
GAPDH genes. For protein stability analysis, the cells
were treated with 10 μM cycloheximide, and then whole
cell lysates were prepared after different durations. The
lysates (15 μg) were then subjected to Western blot ana-
lysis to identify the Myc and tubulin proteins. Protein
levels were quantified using VisionWorksLS version 7.0
software (UVP, Upland, CA, USA).
Assay of growth rate and colony formation in soft agar
For proliferation assay, the cells (2000 cells/well) were
seeded into 96-well culture plate. The cell number was
evaluated by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT)-based semi-automated col-
orimetric assay. For soft agar colony-forming assay,
20000 cells in complete medium containing 0.3% Bacto-
agar were overlaid on 1% agar-complete medium in 60
mm culture dish for two weeks. The colony number
was counted under phase contrast microscopy at 4X
magnification.
Invasion assay
An in vitro invasion assay was performed by analyzing
the ability of tumor cells to penetrate through Matrigel
(BD Biosciences). The cells (2 × 104) were seeded into
the chamber of a 24 trans-well plate preloaded with 0.1
ml Matrigel for 16 hours. The penetrated cells were
fixed with methanol, stained with Giemsa solution,
photographed, and counted.
Statistical analysis
The association of IKKa, IKKb, NF-B p65 and Myc
expression in a total of 21 breast cancer specimens was
analyzed with Fisher exact test (SPSS software for Win-
dows 11.0, SPSS, Inc., Chicago, IL). A probability of
error <5% was regarded as significant.
Results
The expression of Myc is associated with IKKs but not
with NF-B in breast cancer
To identify whether the expression of Myc was asso-
ciated with IKKs/NF-B expressions in vivo, IHC stain-
ing was used to identify the expression of IKKa, IKKb,
Myc and NF-B p65 in a total of 21 breast cancer spe-
cimens. The staining of more than 50% of the cells in
a single field of view and at least 5 fields in a specimen
were designated as positive [Figure 1]. The ratio of
positive staining was 67% (14/21) for IKKa, 57% (12/
21) for IKKb, 67% (14/21) for NF-B p65, and 62%
(13/21) for Myc. When the expression of Myc was
assessed based on nuclear staining, the ratio was 48%
(10/21), similar to the result of a previous study [30].
Statistical analysis showed that Myc expression was
correlated with IKKa and IKKb expression, whereas it
had no correlation with the expression of NF-B p65
(Figure 1). This result suggested that IKKs might regu-
late Myc expression through an NF-B-independent
pathway.
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Suppression of IKK activity decreases Myc protein levels
in MCF7 cells
To explore the effects of the IKKs on Myc expression,
an IKK inhibitor Bay11-7082 [31,32] was used to treat
breast carcinoma MCF7 cells. Bay11-0782 blocked
TNFa-induced NF-B p65 nuclear translocation (Figure
2A), whereas it did not alter the basal level of cytoplas-
mic or nuclear NF-B p65 or p50, suggesting that
Bay11-7082 did not influence basal activity of NF-B.
Bay11-7082 markedly decreased the level of phosphory-
lated and total Myc protein. The Myc-binding partner,
Max, was not affected by Bay11-7082 (Figure 2B).
To distinguish the role of IKKa and IKKb in the regu-
lation of Myc expression, MCF7 cells were transfected
with IKKa or IKKb [either wild-type or kinase-dead
mutant] expression vectors (Figure 2C). Wild-type IKKa
or IKKb increased Myc protein levels, on the other
hand, kinase-dead IKKa or IKKb decreased Myc expres-
sion. Further, Western blot analysis showed that while
the phosphorylation of Myc at Ser62 was increased in
wild-type IKKa- and IKKb-transfected cells and
decreased in kinase-dead mutant transfected cells, the
phosphorylation of Myc at Thr58 was not affected in
any of the transfected or control cells. The expression of
Max was not changed by the manipulation of IKKs
(Figure 2D). Furthermore, we observed a reciprocal
upregulation of IKKa and IKKb (Figure 2D).
Suppression of either IKKa or IKKb slows the degradation
rate of Myc mRNA
To identify whether IKKa or IKKb could increase the
transcription of Myc mRNA, qPCR was used to deter-
mine the relative levels of Myc mRNA in Bay11-7082
treated MCF7 cells and IKK-transfected cells (Figure
3A). Overexpression of either wild-type IKKa or IKKb
slightly increased the level of Myc mRNA. The induc-
tion level was less than two-fold of the control which is
the cut-point of most gene array analyses. Interestingly,
while Bay11-7082 only marginally reduced Myc mRNA
levels, a small increase of Myc mRNA (less than 1.5-fold
of control levels) was observed in both kinase-dead
IKKa- and IKKb-transfected cells. These results sug-
gested that IKKs could increase Myc protein levels in a
transcription-independent manner.
To explore the mechanism which directs the increase
of Myc mRNA in kinase-dead IKKa- and IKKb -trans-
fected cells, we hypothesized that the degradation rate
of Myc mRNA might be prolonged in response to the
decreased Myc protein levels. We used actinomycin D
to block new mRNA synthesis and then determined the
Figure 1 Myc expression level is associated with IKKa and IKKb but not NF-B. IHC staining was used to identify the expression of IKKa,
IKKb, NF-B p65 and Myc in breast cancer specimens (upper panel). Representative pictures of positive and negative staining are shown. Statistic
analysis shows a positive association among IKKa and/or IKKb and Myc expression in 21 breast cancer specimens (lower panel).
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degradation rate of the Myc mRNA by qPCR. The decay
of Myc mRNA was at a comparable rate among Bay11-
7082 treated MCF7 cells and wild-type IKKa- and
IKKb-transfected cells, whereas a prolonged degradation
rate was observed in kinase-dead IKKa- and IKKb-
transfected cells (Figure 3B, C and 3D).
IKKs increase Myc protein stability
Next, we determined the degradation rate of the Myc
protein in Bay11-0782 treated MCF7 cells and in IKK-
transfected cells by Western blot analysis along a time
course after adding a protein synthesis inhibitor, cyclo-
heximide. Bay11-7082 induced a more rapid degradation
rate of Myc protein (Figure 4A). Wild-type IKKa or
IKKb increased the stability of Myc protein. On the
other hand, kinase-dead IKKa or IKKb enhanced Myc
protein degradation (Figure 4B and 4C).
IKKa directly interacts with the Myc protein
Next, we used reciprocal coimmunoprecipitation fol-
lowed by Western blot analysis to identify potential
interactions between IKKs and Myc. The result showed
that IKKa coimmunoprecitated with Myc, indicating a
direct interaction between IKKa and Myc. However, the
interaction between IKKb and Myc was barely detect-
able (Figure 4D). The interaction between IKKa and
Myc was not affected by loss of IKKa activity (Figure
4E), or by the presence of overexpressed wild-type or
kinase-dead IKKb (Figure 4F). This finding was further
supported by confocal microscopy observation. The spe-
cimens from a patient with breast cancer, which stained
positive for IKKa, IKKb and Myc, were dual-stained for
IKKa/Myc or IKKb/Myc. It was observed that IKKa
colocalized with Myc, whereas IKKb and Myc was not
found to be significantly colocalized (Figure 4G).
Figure 2 IKKa and IKKb increase Myc protein level. (A). MCF7 cells were treated with 10 μM Bay11-0782 for 12 hours and then were further
treated with 20 ng/ml TNF-a for 30 minutes. The cytoplasmic and nuclear extracts were subjected to Western blot analysis of NF-B p65
subcellular distribution. Stains of tubulin were used to represent the clearance of cellular fractionation and stains of actin were used as loading
control. (B). MCF7 cells were treated with 10 μM Bay11-0782 for 12 hours, and then the whole cell lysates, the cytoplasmic and nuclear extracts
were prepared. Equal amount of proteins (15 μg/lane) were subjected to Western blotting analysis. (C). MCF7 cells were transfected with IKKa
and IKKb (both wild-type and kinase-dead mutant). The transfected cells were analyzed by Western blotting of IKKa and IKKb.(D). The whole cell
lysates prepared from indicated cells were subjected to Western blot analysis.
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IKKs promote anchorage-independent growth and
invasiveness of MCF7 cells
We next characterized the biological functions of IKKs
by analyzing IKK-transfected cells. Cells overexpressing
either wild-type or kinase-dead IKKa or IKKb showed
comparable growth rates (Figure 5A). However, wild-
type IKKa and IKKb increased cell growth in soft-agar,
a well-defined character of tumorigenesis, and kinase-
dead IKKa and IKKb suppressed this ability of the cells
(Figure 5B). Next, we assayed the ability of IKK-overex-
pressing cells to pass through matrigel, a well-estab-
lished method to determine the invasive activity of
cancer cells. Wild-type IKKa or IKKb overexpressing
cells showed a higher invasive ability than parental
MCF7 cells; by contrast, the invasive ability was
decreased in kinase-dead IKKa or IKKb-transfected cells
(Figure 5C). Because cyclin D1 and Twist are two
important down-stream effectors of Myc and their bio-
logical functions are associated with the invasive/tumori-
genic ability of cancer cells [20,33,34], cyclin D1 and
Twist protein levels were determined by Western blot
analysis. Consistently, the levels of these two proteins
were increased in wild-type IKKa- or IKKb- transfected
cells and decreased in kinase-dead IKKa-or IKKb-
transfected cells (Figure 5D).
IKKs/Myc is a stress-inducible signaling pathway
Because IKKs play an important role in tumor cells
response to various stresses, it was of interest to ask
whether common chemotherapeutic agents for breast
Figure 3 IKKa and IKKb increase Myc in a transcription-independent manner. (A) MCF7 cells were treated with 10 μM Bay11-0782 for 12
hours. The RNA was extracted from indicated cells and random-primed reverse transcribed into cDNA. The relative expression of Myc was
determined by qPCR. The expression of GAPDH was used as an internal control. The specificity of the primer set for Myc and GAPDH was
demonstrated by agarose electrophoresis of PCR product (inserted figure) and by analysis of dissociation curve (data not shown). Each data
represents mean ± SD calculated from two independent experiments. To determine the degradation rate of Myc mRNA, the cDNAs were
prepared from (B) MCF7 cells were treated with 10 μM Bay11-0782 for 12 hours, (C) MCF7, wild-type IKKa and IKKb transfected cells, and (D)
MCF7, kinase-dead IKKa and IKKb transfected cells. The relative level of Myc mRNA was determined by qPCR and expressed along a time course
after adding actinimycin D. Each data represents mean ± SD calculated from two independent experiments.
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Figure 4 IKKa and IKKb increase Myc protein stability. The stability of Myc protein was analyzed by Western blot analysis of the whole cell
lysates prepared from (A) MCF7 with or without a 12 hours, 10 μM Bay11-0782 treatment (B) wild-type and kinase-dead IKKa transfected cells
(C) wild-type and kinase-dead IKKb transfected cells along a time course after adding cycloheximide. The stain of tubulin was used as loading
control. The reading of Myc density was normalized to the reading of tubulin density. Each data represents mean ± SD calculated from two
independent experiments. Whole cell lysates were prepared from (D) MCF7 cells, (E) wild-type and kinase-dead IKKa transfected cells, and (F)
wild-type and kinase-dead IKKb transfected cells were subjected to coimmuoprecipitation using indicated antibodies. The precipitated complex
was further Western blot analyzed the corresponding proteins shown in the figure. (G) Confocal microscopy observation. Breast cancer tissues
which were previously identified positive or negative for IKKa, IKKb and Myc expressions by IHC staining were used. The slides were dual stained
with rabbit anti-IKKa/mouse anti-Myc antibodies coupled with FITC-conjugated goat anti-rabbit IgG/Rodamine-conjugated donkey anti-mouse
IgG antibodies or goat anti-IKKb/mouse anti-Myc antibodies coupled with FITC-conjugated donkey anti-goat IgG/Rodamine-conjugated donkey
anti-mouse IgG antibodies, respectively.
Yeh et al. Molecular Cancer 2011, 10:53
http://www.molecular-cancer.com/content/10/1/53
Page 7 of 12
cancer treatment could induce IKK and Myc activation.
We used doxorubicin (200 nM; IC50 for MCF7 cells)
alone or combined with Bay11-0782 to treat MCF7
cells. Cells were exposed to doxorubicin with or without
Bay11-0782 for either 24-hour or for 3-hour followed by
a 24-hour release in the presence or absence of Bay11-
0782. Doxorubicin induced IKKs activation, with induc-
tion levels highest in cells released from a 3-houre dox-
orubicin treatment. When Bay11-0782 was re-added to
the cells released from a 3-hour treatment with doxoru-
bicin with or without Bay11-0782, decreased levels of
doxorubicin-induced IKKs activation were observed.
IKK activity returned to control levels after a 24-hour
Bay11-0782 treatment. (Figure 6A). Consequently, the
phosphorylation of Myc at Ser 62 was increased by dox-
orubicin, and the highest level of induction was achieved
in cells released from a 3-hour doxorubicin treatment
with or without Bay11-0782 cotreatment. Re-addition of
Bay11-0782 blocked this induction. The phosphorylation
of Myc at Thr58 remained at a relatively constant level
following all treatments. The level of Myc protein was
changed with a consistent pattern as the status of phos-
phorylated Myc Ser62. Cyclin D1 and Twist levels were
also altered in a similar manner (Figure 6A). In addition,
Western blot analysis showed that NF-B was not
affected by these treatments (Figure 6B).
IKKs/Myc activated by doxorubicin promotes
tumorigenesis and invasiveness of MCF7 cells
Because cyclin D1 and Twist proteins were increased in
MCF7 cells following a 3-hour doxorubicin exposure,
we characterized whether the tumorigenic and invasive
ability of MCF7 cells was subsequently enhanced.
Indeed, the cells released from a 3-hour doxorubicin
treatment increased their ability to grow in soft-agar
and to pass through matrigel. Co-treatment with Bay11-
0782 partially suppressed these activities, and re-addi-
tion of Bay11-0782 after released from doxorubicin
markedly decreased these activities to lower than the
levels of the untreated control (Figure 6C and 6D).
These results were further supported by analyzing the
effect of doxorubicin on IKK-transfected cells. Following
the same treatments as above, the protein levels of Myc,
cyclin D1, and Twist were increased in wild-type IKKa-
and IKKb-transfected cells (Figure 7A and 7C), but were
not changed in kinase-dead IKKa- and IKKb-transfected
cells (Figure 7B and 7D).
Discussion
In this study, we explored the relationship between IKKs
and Myc expression in breast cancers. IHC staining of
breast cancer specimens indicated that the expression of
Myc was associated with IKKa and IKKb, but was
Figure 5 IKKa and IKKb increase tumorigenesis and invasiveness of MCF7 cells. (A) MTT assay was used to analyze the growth rate of
indicated cells. Each data represents mean ± SD calculated from three independent experiments, and there are four wells for each point in a
single experiment. (B) Assay of colony-forming ability in soft-agar. Each experiment have three 60 mm dishes and each data represents mean ±
SD calculated from two independent experiments. (C) Assay of invasive ability of indicated cells. Each experiment have three trans-wells and
each data represents mean ± SD calculated from two independent experiments. (D) Western blot analysis of the expression of cyclin D1 and
twist protein in the indicated cells.
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unrelated to that of NF-B. We demonstrated that IKKa
and IKKb did not enhance Myc transcription but
instead increased Myc protein stability. Importantly, we
also showed that the commonly used anticancer drug,
doxorubicin, activated IKKs, and thereby increased Myc
protein levels. Myc plays an important role in tumor
progression and is associated with metastasis and a poor
outcome of breast cancers [7,17,19]. However, there is
still no reliable drug which can effectively target Myc.
Our study indicates that one possible way to block Myc
is by inhibition of IKKs.
It is well known that IKKs trigger IBa degradation
and subsequent activation of NF-B [10]. However, our
results showed that IKKa and IKKb regulated Myc
expression levels without altering NF-B activation. NF-
B activation is tightly auto-regulated by inducing the
expression of its natural inhibitor, IBa. For example, in
response to TNFa stimulation, IBa is degraded during
the first 15 minutes and quickly restored in one hour.
Therefore, we hypothesized that transfection of wild-
type IKKa and IKKb may have transiently activate NF-
B, but that the activity of NF-B subsequently returned
Figure 6 IKKs-Myc pathway is inducible. (A) MCF7 cells were treated with 10 μM Bay11-0782 alone, or 200 nM doxorubicin in the presence or
absence of 10 μM Bay11-0782 for 24 hours (Dox, Bay, and Bay/Dox), or 3-hr short-term pulse followed by 24 hours release in the presence or
absence of Bay11-0782 (Dox3-R, Bay/Dox3-R, and Bay/Dox3-R/Bay). Whole cells lysates were subjected to Western blot analysis. (B) MCF7 cells
were treated 200 nM doxorubicin with or without 10 μM Bay11-0782 for 24 hours. The cytoplasmic and nuclear lysates were subjected to
Western blotting. (C) MCF7 cells were treated with 200 nM doxorubicin in the presence or absence of 10 μM Bay11-0782 for 3 hours. The cells
were then seeded into soft-agar in complete medium with or without 10 μM Bay11-0782 for two weeks. Each experiment have three 60 mm
dishes and each data represents mean ± SD calculated from two independent experiments. (D) MCF7 cells were treated as shown, and then the
ability of cells to penetrate matrigel was determined. Each experiment have three trans-wells and each data represents mean ± SD calculated
from two independent experiments.
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to basal levels due to the balance between NF-B and
IBa.
In this study, we showed that suppression of IKK
activity by transfection of kinase-dead IKKa or IKKb
decreased Myc protein levels, whereas slightly increased
the Myc mRNA levels. Our results demonstrated that
the change in Myc protein levels was not related to the
transcription of Myc, consistent with a previous study
performed in neuroblastoma [35]. Our study further
demonstrated that the turn-over rate of the Myc mRNA
was prolonged in kinase-dead IKKa- and IKKb-trans-
fected cells. Interestingly, Bay11-0782 did not show this
activity, suggesting that it may have other effect on
mRNA stability. While the underlying mechanism
remains unknown, our result may help explain the con-
flicting results in analyzing the relative levels of mRNA
and protein of certain genes.
The stability of Myc is controlled by its phosphoryla-
tion at Ser62 and Thr58 [16]. In this study, we showed
that IKKa and IKKb increased Myc protein stability by
regulating its phosphorylation status at Ser62. We
further demonstrated that IKKa but not IKKb directly
interacted with Myc. While the pathway connecting
IKKb to Myc remains to be identified, our study demon-
strated a reciprocal upregulation between IKKa and
IKKb, indicating that IKKb may indirectly increase Myc
through IKKa. However, it is of particular interest to
determine whether IKKb may also affect Myc through
regulation of related molecules, such as PP2A or cip2A.
A comparable growth rate was observed among paren-
tal MCF7 cells and IKKs-transfected cells. Because
Bay11-0872 indeed decreased MCF cell growth [data
not shown], it is likely that un-identified pathways
which can compensate for Myc activity are developed
during the selection of kinase-dead IKKa- and IKKb-
transfected cells. In addition, our result indicated that
the invasive ability induced by Myc could be separated
from the growth potential of cancer cells and that Myc
Figure 7 IKK activity is necessary for doxorubicin to increase Myc, cyclin D1 and twist protein levels in MCF7 cells. The cells (A) MCF/
IKKa-WT, (B) MCF/IKKa-KD, (C) MCF/IKKb-WT, and (D) MCF/IKKb-KD were treated with 200 nM doxorubicin for 3hours, and then were released
with complete medium for further 24 hours. The cytoplasmic and nuclear extracts were subjected to Western blot analysis.
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activity was indispensable for the enhanced invasiveness.
Our results are consistent with the data from a previous
study using another breast cancer cell line MDA-MB
231 [17].
Based on gene array analysis, Myc has been shown to
regulate a set of gene signatures associated with metas-
tasis and poor-outcome of breast cancers [17]. Abnor-
mal expression of Myc promotes the epithelial to
mesenchymal transition and metastasis [14,18,36]. In
this study, we showed that Myc increased the tumori-
genic and invasive ability of MCF7 cells. We also identi-
fied that the levels of cyclin D1 and Twist were
consistently altered along with the Myc protein level. It
is reasonable to conclude that Myc enhances tumorigen-
esis, at least in part, through the upregulation of cyclin
D1 and Twist. However, overexpression of Myc in a
non-invasive, transformed breast cell line [MCF10A]
does not promote its invasive ability, suggesting that
Myc is a necessary but not sufficient factor for cancer
cell invasiveness [22]. It is hypothesized that Myc should
cooperate with other factors to enhance the invasive
activity of the cells. In this study, Myc was increased
downstream of IKKa and IKKb activation. Both IKKa
and IKKb also regulate the expression of multiple genes
that are involved in cancer cell progression and metasta-
sis. Therefore, it is possible that a Myc-centered net-
work cooperates and/or merges with an IKK-centered
network to enhance the tumorigenic and invasive activ-
ity of cancer cells. These complicated interactions
should be further characterized through systemic genetic
studies.
In this study, we provided evidence that doxorubicin
increased Myc protein levels probably through activat-
ing IKKa and IKKb. The cells that were released from
doxorubicin increased their invasive and tumorigenic
activities, and suppression of IKK activation blocked
these phenotypes. Myc regulates many downstream
gene expressions which share a similarity between
embryonic stem cells and cancer cells [37,38]. It is
important to determine whether doxorubicin stimu-
lates re-growth and progression of cancer cells in vivo.
On the other hand, IKKs are major mediators linking
inflammation and cancer progression [10,39]. We have
not tested other stimulus, such as inflammation-related
cytokines, that may have similar effects on the IKK/
Myc pathway; however, it is possible that the death of
cancer cells caused by therapeutic treatment may trig-
ger an inflammation response, which activates IKKs
and Myc in the remaining cancer cells, and subse-
quently stimulates cancer progression. In addition,
IKKs and Myc are widely expressed in various cancers.
For example, IKK and Myc have been separately
reported to be necessary for hepatocellular carcinoma
cell growth and invasiveness [2,8]; it is therefore likely
that our finding may be applicable to other cancers.
Taken together, our results suggested that IKKs/Myc
might be important therapeutic targets for breast can-
cer and provided a rationale for the use of IKK inhibi-
tors following chemotherapy to suppress the
treatment-enhanced tumor progression.
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